Last reviewed · How we verify
Antiinflammatories
At a glance
| Generic name | Antiinflammatories |
|---|---|
| Sponsor | Universidad Complutense de Madrid |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis (PHASE3)
- Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI (PHASE1, PHASE2)
- Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting
- Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (PHASE1, PHASE2)
- In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors (NA)
- Anti-Inflammatory Effects of Pecan Nut Oil Supplementation in Adults With Overweight: A Randomized Controlled Parallel-Group Clinical Trial (NA)
- PBMC as Biomarkers of Diabetic Cardiomyopathy
- Efficacy of Chemically Distinct Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Pain Phenotypes in Adhesive Capsulitis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antiinflammatories CI brief — competitive landscape report
- Antiinflammatories updates RSS · CI watch RSS
- Universidad Complutense de Madrid portfolio CI